6.
Li X, Poire A, Jeong K, Zhang D, Ozmen T, Chen G
. C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer. Nat Commun. 2024; 15(1):4485.
PMC: 11130309.
DOI: 10.1038/s41467-024-48637-y.
View
7.
Barresi V, Ieni A, Bolignano D, Magno C, Buemi M, Barresi G
. Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade. Oncol Rep. 2010; 24(2):305-10.
DOI: 10.3892/or_00000860.
View
8.
Chen J, Sun Z, Chen L, Xu F, Zhao Y, Li G
. C5aR deficiency attenuates the breast cancer development via the p38/p21 axis. Aging (Albany NY). 2020; 12(14):14285-14299.
PMC: 7425439.
DOI: 10.18632/aging.103468.
View
9.
Xiao X, Yeoh B, Vijay-Kumar M
. Lipocalin 2: An Emerging Player in Iron Homeostasis and Inflammation. Annu Rev Nutr. 2017; 37:103-130.
DOI: 10.1146/annurev-nutr-071816-064559.
View
10.
Karoui K, Viau A, Dellis O, Bagattin A, Nguyen C, Baron W
. Endoplasmic reticulum stress drives proteinuria-induced kidney lesions via Lipocalin 2. Nat Commun. 2016; 7:10330.
PMC: 4735759.
DOI: 10.1038/ncomms10330.
View
11.
Nishimura S, Yamamoto Y, Sugimoto A, Kushiyama S, Togano S, Kuroda K
. Lipocalin-2 negatively regulates epithelial-mesenchymal transition through matrix metalloprotease-2 downregulation in gastric cancer. Gastric Cancer. 2022; 25(5):850-861.
PMC: 9365736.
DOI: 10.1007/s10120-022-01305-w.
View
12.
Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A
. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97.
DOI: 10.1016/S0140-6736(10)61121-X.
View
13.
Torti S, Torti F
. Iron and Cancer: 2020 Vision. Cancer Res. 2020; 80(24):5435-5448.
PMC: 8118237.
DOI: 10.1158/0008-5472.CAN-20-2017.
View
14.
Santiago-Sanchez G, Pita-Grisanti V, Quinones-Diaz B, Gumpper K, Cruz-Monserrate Z, Vivas-Mejia P
. Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer. Int J Mol Sci. 2020; 21(12).
PMC: 7352275.
DOI: 10.3390/ijms21124365.
View
15.
Schreiber R, Old L, Smyth M
. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70.
DOI: 10.1126/science.1203486.
View
16.
Porta C, Riboldi E, Ippolito A, Sica A
. Molecular and epigenetic basis of macrophage polarized activation. Semin Immunol. 2015; 27(4):237-48.
DOI: 10.1016/j.smim.2015.10.003.
View
17.
Marques O, Porto G, Rema A, Faria F, Cruz Paula A, Gomez-Lazaro M
. Local iron homeostasis in the breast ductal carcinoma microenvironment. BMC Cancer. 2016; 16:187.
PMC: 4779214.
DOI: 10.1186/s12885-016-2228-y.
View
18.
Thrift A, Wenker T, El-Serag H
. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023; 20(5):338-349.
DOI: 10.1038/s41571-023-00747-0.
View
19.
Tong Z, Kunnumakkara A, Wang H, Matsuo Y, Diagaradjane P, Harikumar K
. Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008; 68(15):6100-8.
PMC: 2714276.
DOI: 10.1158/0008-5472.CAN-08-0540.
View
20.
Jaberi S, Cohen A, DSouza C, Abdulrazzaq Y, Ojha S, Bastaki S
. Lipocalin-2: Structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021; 142:112002.
DOI: 10.1016/j.biopha.2021.112002.
View